Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Akero Therapeutics Inc Market Cap
The Akero Therapeutics Inc (AKRO) share price is expected to increase by 65.22% over the next year. This is based on calculating the average 12-month share price estimate provided by 1 stock analysts who have covered AKRO. Price targets range from $40.00 at the low end to $40.00 at the high end. The current analyst consensus for AKRO is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
AKRO is a stock in Health Care which has been forecasted to be worth $40.00 as an average. On the higher end, the forecast price is $40.00 USD by aspen mori from Bank of America Securities and on the lower end AKRO is forecasted to be $40.00 by aspen mori from Bank of America Securities.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| ed arce H.C. Wainwright | Buy | $40.0 | maintained | Dec 19, 2023 |
| michael yee Jefferies | Buy | $35.0 | reiterated | Nov 15, 2023 |
| patrick dolezal LifeSci Capital | Buy | $60.0 | maintained | Nov 14, 2023 |
| edward nash Canaccord Genuity | Buy | $59.0 | maintained | Oct 22, 2023 |
| eliana merle UBS | Buy | $39.0 | maintained | Oct 12, 2023 |
| joshua schimmer Evercore ISI | Buy | $36.0 | maintained | Oct 11, 2023 |
| liisa bayko Evercore ISI | Buy | $36.0 | maintained | Oct 11, 2023 |
| michael ulz Morgan Stanley | Buy | $33.0 | maintained | Oct 10, 2023 |
| eric joseph J.P. Morgan | Buy | $41.0 | rated | Oct 10, 2023 |
| prakhar agrawal Cantor Fitzgerald | Buy | $69.0 | reiterated | Oct 10, 2023 |
| matthew harrison Morgan Stanley | Hold | $40.0 | maintained | Nov 7, 2022 |
| aspen mori Bank of America Securities | Buy | $40.0 | initiatedcoverage | Sep 10, 2021 |
| etzer darout BMO Capital | Buy | $54.0 | initiatedcoverage | Feb 26, 2021 |
| yasmeen rahimi Piper Sandler | Buy | $43.0 | maintained | Feb 13, 2020 |
Akero Therapeutics, Inc., a clinical-stage company, engages in the development of transformational treatments for patients with serious metabolic diseases, including non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. Its lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. The company is also conducting a Phase 2b clinical trial to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.
When did it IPO
2019
Staff Count
51
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Dr. Andrew Cheng M.D., Ph.D.
Market Cap
$1.34B
In 2023, AKRO generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that AKRO's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2019
Revenue From 2020
Revenue From 2021
Revenue From 2022
OMCL-USD
$28.58
OLPX-USD
$2.14
FWRD-USD
$39.67
EXTR-USD
$11.83
$5.74
NTCT-USD
$22.26
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
